re: Ann: Transcript of CAN-003 data conferenc... Dr Monk commented on the competitive landscape and only mentioned
Parp inhibitors and anti angiogenesis. He didn't mention shRNA , which is what FANG is.
Their trial was on very late stage OC iiic/iv.
Their results to my eye weren't as impressive as CVacs', but they are working with a slightly different group of patients, where PRR is now focused on second remission. The group that the most recent results and update are from.
Ann: Transcript of CAN-003 data conference call , page-23
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.060(20.3%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.5¢ | 33.5¢ | $6.427M | 18.03M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 133736 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |